The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...

An indirect treatment comparison shows that dupilumab and tezepelumab yield broadly similar clinical benefits in patients ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending dupilumab as an ...

SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections cut total nasal polyps score by ...

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well, Regeneron Pharmaceuticals and Sanofi ...

Please provide your email address to receive an email when new articles are posted on . Wenyi Chen, of the department of otolaryngology-head and neck surgery at Third Affiliated Hospital of Sun ...

A comprehensive study analyzing data from nearly 240,000 women has found that estrogen-containing hormonal contraceptives are associated with a significantly lower risk of chronic rhinosinusitis ...